Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 15/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.40 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15464639 | 0.85 | USP2 (0.44) | CYP11B2CYP11B1 | |
| SCHEMBL15464353 | 0.79 | PTPN1 (0.45) | DUSP3SMURF2SMURF1 | |
| SCHEMBL1686549 | 0.79 | TRPV1 (0.59) | CYP11B2CYP11B1DUSP3TRPV1SMURF2 | |
| SCHEMBL15464858 | 0.75 | SMURF1 (0.47) | CYP11B2CYP11B1DUSP3SLC22A12SMURF2 | |
| SCHEMBL15464509 | 0.74 | XDH (0.59) | XDH | |
| SCHEMBL5591183 | 0.73 | IP6K1 (0.52) | DUSP3SMURF2SMURF1 | |
| SCHEMBL15464604 | 0.73 | CYP11B2 (0.48) | CYP11B2CYP11B1 | |
| SCHEMBL15465069 | 0.72 | CYP11B2 (0.44) | CYP11B2CYP11B1XDH | |
| SCHEMBL4076415 | 0.72 | PTPN1 (0.67) | DUSP3SMURF2SMURF1 | |
| SCHEMBL5590836 | 0.72 | IP6K1 (0.58) | DUSP3SMURF2SMURF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926308-B2 | N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-9926308-B2 | N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-9926308-B2 | N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| EP-2880027-B1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-09-28 | — | — | EP | disclosed |
| US-20160159784-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159784-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159784-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-2880027-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045823-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045823-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045823-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014019967-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| US-20090209779-A1 | Process for preparing intermediates of HMG-CoA reductase inhibitors | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209779-A1 | Process for preparing intermediates of HMG-CoA reductase inhibitors | HMGCR, COASY, PCSK9 | CYP11B2 60/4885CYP11B1 29/4885DUSP3 3875/4885 |
| US-20140045823-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | GPR180, GPR119, CNR1 | CYP11B2 614/4885CYP11B1 613/4885DUSP3 4798/4885 |
| US-20160159784-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | GPR119, FFAR1, FFAR2 | CYP11B2 795/4885CYP11B1 713/4885DUSP3 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.